Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody™ platform.
Faron will develop Clevegen®, a novel anti-Clever-1 antibody, for the treatment of selected metastatic or inoperable tumours. It’s great to see an ABZENA Inside product move closer towards the clinic, demonstrating Abzena’s ability to provide the technologies and support needed to forward our partners’ products into clinical trials. The news follows on from the announcement made on 8 August that Abzena had completed the GMP drug substance manufacture of Clevegen®.
For more information, see Faron’s full announcement: http://otp.investis.com/clients/uk/faron/rns/regulatory-story.aspx?newsid=1185609&cid=2223